Cargando…

Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis

BACKGROUND: Current practice guidelines non-preferentially recommend cefazolin, cefoxitin, cefotetan, or ampicillin-sulbactam as first line choices for antibiotic prophylaxis in hysterectomy. We undertook a systematic review to determine whether cefazolin, with no anti-anaerobic activity, is as effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Pop-Vicas, Aurora, Johnson, Stephen, Safdar, Nasia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631282/
http://dx.doi.org/10.1093/ofid/ofx163.1732
_version_ 1783269429608448000
author Pop-Vicas, Aurora
Johnson, Stephen
Safdar, Nasia
author_facet Pop-Vicas, Aurora
Johnson, Stephen
Safdar, Nasia
author_sort Pop-Vicas, Aurora
collection PubMed
description BACKGROUND: Current practice guidelines non-preferentially recommend cefazolin, cefoxitin, cefotetan, or ampicillin-sulbactam as first line choices for antibiotic prophylaxis in hysterectomy. We undertook a systematic review to determine whether cefazolin, with no anti-anaerobic activity, is as effective as β-lactam antibiotics with anti-anaerobic activity at preventing surgical site-infection (SSI) after abdominal or vaginal hysterectomy. METHODS: We searched PubMed, Scopus, Web of Science, Cochrane Central, and conference proceedings for randomized controlled trials (RCT) in any language up to May 16, 2016. Main search terms included cephalosporins, antibiotic prophylaxis, hysterectomy, surgical wound infection, clinical trials, and random allocation. We included only RCT that measured SSI – our primary outcome – defined as superficial, deep, or organ space. We excluded trials of β-lactams no longer in clinical use. We used predefined data extraction templates, including bias assessment indicators, and performed meta-analyses with random-effects models. RESULTS: Fourteen RCTs met inclusion criteria. There were 98 (5%) SSI among 1,903 patients in the cefazolin group, and 78 (4%) SSI among 1,772 patients in the comparator β-lactam (cefoxitin, cefotetan, cefotaxime, ceftriaxone, ampicillin, amoxicillin/clavulanate, or penicillin) group. The summary estimate showed no significant benefit for cefazolin vs. other β-lactam in reducing SSI (Risk Ratio 1.19; 95% CI 0.88 – 1.62, P = 0.23). Cefazolin had a higher SSI risk when compared with cefoxitin or cefotetan (Risk Ratio 1.67; 95% CI 1.03–2.72, P = 0.04), and a trend for higher SSI risk when compared with cefoxitin, cefotetan, or amoxicillin/clavulanate (Risk Ratio 1.56; 95% CI 0.99–2.49, P = 0.06). Most studies were limited to hysterectomies for benign indications, had variability in prophylaxis duration (single vs. multiple doses) and had unclear or high risk of bias. CONCLUSION: Β-lactam antibiotics with good anti-anaerobic spectrum may be preferable to cefazolin for SSI prevention post-abdominal or vaginal hysterectomy. Antimicrobial prophylaxis for hysterectomy in the setting of advanced malignancy deserves further study. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-5631282
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56312822017-11-07 Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis Pop-Vicas, Aurora Johnson, Stephen Safdar, Nasia Open Forum Infect Dis Abstracts BACKGROUND: Current practice guidelines non-preferentially recommend cefazolin, cefoxitin, cefotetan, or ampicillin-sulbactam as first line choices for antibiotic prophylaxis in hysterectomy. We undertook a systematic review to determine whether cefazolin, with no anti-anaerobic activity, is as effective as β-lactam antibiotics with anti-anaerobic activity at preventing surgical site-infection (SSI) after abdominal or vaginal hysterectomy. METHODS: We searched PubMed, Scopus, Web of Science, Cochrane Central, and conference proceedings for randomized controlled trials (RCT) in any language up to May 16, 2016. Main search terms included cephalosporins, antibiotic prophylaxis, hysterectomy, surgical wound infection, clinical trials, and random allocation. We included only RCT that measured SSI – our primary outcome – defined as superficial, deep, or organ space. We excluded trials of β-lactams no longer in clinical use. We used predefined data extraction templates, including bias assessment indicators, and performed meta-analyses with random-effects models. RESULTS: Fourteen RCTs met inclusion criteria. There were 98 (5%) SSI among 1,903 patients in the cefazolin group, and 78 (4%) SSI among 1,772 patients in the comparator β-lactam (cefoxitin, cefotetan, cefotaxime, ceftriaxone, ampicillin, amoxicillin/clavulanate, or penicillin) group. The summary estimate showed no significant benefit for cefazolin vs. other β-lactam in reducing SSI (Risk Ratio 1.19; 95% CI 0.88 – 1.62, P = 0.23). Cefazolin had a higher SSI risk when compared with cefoxitin or cefotetan (Risk Ratio 1.67; 95% CI 1.03–2.72, P = 0.04), and a trend for higher SSI risk when compared with cefoxitin, cefotetan, or amoxicillin/clavulanate (Risk Ratio 1.56; 95% CI 0.99–2.49, P = 0.06). Most studies were limited to hysterectomies for benign indications, had variability in prophylaxis duration (single vs. multiple doses) and had unclear or high risk of bias. CONCLUSION: Β-lactam antibiotics with good anti-anaerobic spectrum may be preferable to cefazolin for SSI prevention post-abdominal or vaginal hysterectomy. Antimicrobial prophylaxis for hysterectomy in the setting of advanced malignancy deserves further study. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2017-10-04 /pmc/articles/PMC5631282/ http://dx.doi.org/10.1093/ofid/ofx163.1732 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Pop-Vicas, Aurora
Johnson, Stephen
Safdar, Nasia
Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis
title Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis
title_full Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis
title_fullStr Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis
title_full_unstemmed Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis
title_short Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis
title_sort should cefazolin be the first-line antimicrobial prophylaxis choice in patients undergoing hysterectomy? a systematic review and meta-analysis
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631282/
http://dx.doi.org/10.1093/ofid/ofx163.1732
work_keys_str_mv AT popvicasaurora shouldcefazolinbethefirstlineantimicrobialprophylaxischoiceinpatientsundergoinghysterectomyasystematicreviewandmetaanalysis
AT johnsonstephen shouldcefazolinbethefirstlineantimicrobialprophylaxischoiceinpatientsundergoinghysterectomyasystematicreviewandmetaanalysis
AT safdarnasia shouldcefazolinbethefirstlineantimicrobialprophylaxischoiceinpatientsundergoinghysterectomyasystematicreviewandmetaanalysis